Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5924 - Assessment of bleeding risk by sonoclot in acute lymphoblastic leukemia

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Site

Leukaemia

Presenters

Kundan Mishra

Citation

Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286

Authors

K. Mishra1, A. JANDIAL1, A. Meshram1, R. Sandal1, D. Lad1, G. Prakash1, A.R. Khadwal1, R. Dhiman2, N. Varma1, S.C. Varma1, P. Malhotra1

Author affiliations

  • 1 Internal Medicine, PGIMER, 160012 - Chandigarh/IN
  • 2 Hepatology, PGIMER, 160012 - Chandigarh/IN
More

Resources

Abstract 5924

Background

At the same level of thrombocytopenia, patients with acute lymphoblastic leukemia (ALL), receive more prophylactic platelet transfusion in comparison to immune thrombocytopenia (ITP). Routine investigation cann’t differentiate the risk of bleeding between ALL and ITP. Sonoclot is a global test of coagulation, a bed side tool, also assesses platelet function. It is widely used in cardiac surgery and hepatology to assess need for blood plasma and platelet transfusion. Aim of the study was to evaluate role of sonoclot in assessing the risk of bleeding in ALL with severe thrombocytopenia.

Methods

In this prospective observational study, twenty-five cases of ALL and fifty cases of ITP (control) were included. All patients included had platelet counts lower than 20000/μL and there was no evidence of any active bleeding. Blood samples were evaluated by conventional coagulation tests as well as by Sonoclot. Sonoclot measures activated clotting time (ACT), clot rate (R1) and platelet function (PF).

Results

Table: 1041P

Comparison of ALL and Control (ITP)

ITP (n = 50)ALL (n = 25)
Parameters(mean ± SD)(mean ± SD)pNormal Value
Platelet (/μL)9536.73 ± 5048.0512240 ± 4576.02NS150000-450000
Prothombin time (seonds)14.1 ± 1.4314.72 ± 2.13NS11-14
Activated partial thromboplastin time (seconds)29.66 ± 1.9929.77 ± 2.13NS25-35
ACT (seconds)251.1 ± 37.97260.16 ± 51.2NS100-155
CR (unit)22.17 ± 6.4319.56 ± 4.550.3719-35
PF (unit)1.54 ± 0.720.94 ± .830.007>1.6

Both the groups were matched for platelet count. There was no statistically significant difference between two groups when prothrombin time and activated partial thromboplastin time were compared. On sonoclot analysis, the ACT did not show any difference in the two groups, and though clot rate (CR) was different in two groups, it was not statistically significant. However, platelet function (PF) was significantly lower in the ALL than the ITP group (Table).

Conclusions

This is the first study to the best of our knowledge demonstrating the use of sonoclot in ALL with severe thrombocytopenia. We conclude that sonoclot, a point of care device, can assess the risk of bleeding amongst patients with ALL.

Clinical trial identification

Legal entity responsible for the study

Kundan Mishra.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.